BASFs Nutrition & Health Division to Focus on Growth and Increased Competitiveness
BASF is implementing a series of measures within the Nutrition & Health division to strengthen the competitiveness of its Performance Products segment. The Nutrition & Health division bundles BASF’s products and solutions for human and animal nutrition, the flavor and fragrance industry, as well as the pharmaceutical industry.
BASF is adjusting its product portfolio to better meet changing consumer needs and regional demands. In Asia, BASF is building a citral plant with its partner Petronas to meet the growing demand of customers in the flavor and fragrance industry in the region. The first plants of the complex are expected to come on stream in 2016. At the same time, BASF will focus its production in the growing market of omega-3 fatty acids on the attractive market segment for highly concentrated omega-3 fatty acids and plans to sell the Norwegian Brattvåg site. BASF produces low concentrated omega-3 fatty acids at this site.
Marketing, sales and administration will be better adjusted to regional market dynamics. A global team responsible for marketing and innovation will in future support the development of customer-oriented products and solutions as well as faster market launches of new products. BASF aims to accelerate the innovation cycle of products for its customers through strategic partnerships.
Due to the planned measures about 260 positions in production, marketing and administration will be reduced globally by end of 2015. Consultations with the responsible employee representatives will be conducted.
“We aim to strengthen our position in the growing nutrition and health market. Through these measures we will adapt our business to better meet market and customer needs. At the same time, we will improve our profitability,” said Saori Dubourg, President of BASF’s Nutrition & Health division.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.